Epigenetic Modification and Retinal Degeneration: Evidence of New Potential Therapeutic Targets
Epigenetic Modification and Retinal Degeneration: Evidence of New Potential Therapeutic Targets
复制标题
表观遗传修饰和视网膜变性：新潜在治疗靶点的证据
DOI：
--
复制
发表时间：
2019
期刊：
影响因子：
--
通讯作者：
Danian Chen
中科院分区：
文献类型：
--
作者：
Yimeng Fan;Danian Chen
色素性视网膜炎（Retinitis Pigmentosa，RP）是一组影响感光细胞并导致人类失明的遗传性神经退行性视网膜疾病。表观遗传修饰，包括DNA甲基化，组蛋白翻译后修饰和核小体定位的变化，调节基因表达，细胞分化和发育，而不是DNA序列的改变。在RP的发病机制中，表观遗传修饰起着重要作用，包括DNA甲基转移酶（DNMTs）、聚ADP核糖聚合酶（PARP）、组蛋白脱乙酰酶（HDACs）、Bmi 1、组蛋白H3赖氨酸三甲基化（H3 K27 me 3）和PI 3 K-Akt通路。目前对RP还没有有效的治疗方法，但表观遗传修饰可能为RP的治疗提供新的思路。在这篇综述中，我们提供了一个概述的表观遗传修饰参与RP和证据的新的潜在的治疗目标RP。
Retinitis Pigmentosa (RP) is a group of hereditary neurodegenerative retinal diseases affecting photoreceptor cells and causing blindness in humans. Epigenetic modification, including DNA methylation, histone post-translational modifications and changes in nucleosome positioning, regulates gene expression, cellular differentiation and development that do not result from alterations in the DNA sequences. In the pathogenesis of RP, epigenetic modifications played an important role, including DNA Methyltransferases (DNMTs), Poly-ADP-Ribose Polymerase (PARP), Histone Deacetylases (HDACs), Bmi1, histone H3 lysine trimethylation at H3K27 (H3K27me3), and PI3K-Akt pathway. At present, we do not have effective therapy for RP, but epigenetic modification may shed light on its therapy. In this review, we provided an overview of the epigenetic modifications involved in RP and evidence of new potential therapeutic targets for RP.